8-K: United Health Products Amends Stock Purchase Agreement with White Lion Capital

United Health Products has further amended its Common Stock Purchase Agreement with White Lion Capital, modifying the purchase price calculation for shares.

Summary

• United Health Products, Inc. has amended its Common Stock Purchase Agreement (CSPA) with White Lion Capital, LLC for the second time.
• The amendment, effective June 20, 2024, revises the formula for calculating the purchase price of the company's common stock.
• The purchase price will now be the lower of 93% (or 95% if trading on a national exchange) of the volume-weighted average price (VWAP) over five trading days or the closing price on the day the company exercises its right to sell shares, subject to a floor price of $0.25 per share.
• If the stock price is below the floor price and White Lion waives the floor, the purchase price will be 90% of the lower of the three lowest VWAPs over five days or the most recent closing price.

Sentiment

Score: 4

Explanation: The amendment is not particularly positive for existing shareholders due to the discounted purchase price and potential dilution. While it provides a source of capital, the terms are not highly favorable.

Positives

• The amendment provides a mechanism for the company to sell shares to White Lion Capital.
• The agreement includes a floor price of $0.25 per share, which may provide some protection against extreme price drops.

Negatives

• The purchase price is discounted from the market price, which could dilute existing shareholders.
• The potential for a lower purchase price if the stock trades below the floor price and White Lion waives the floor could further reduce the value received by the company.

Risks

• The discounted purchase price could lead to dilution of existing shareholders.
• The floor price waiver clause could result in the company receiving less value for its shares if the stock price is low.
• The reliance on a single investor for capital could pose a risk if White Lion's investment strategy changes.

Future Outlook

The company may continue to sell shares to White Lion Capital under the terms of the amended agreement.

Management Comments

• Brian Thom, Chief Executive Officer, signed the amendment on behalf of United Health Products, Inc.

Industry Context

This type of agreement is common for small-cap companies seeking to raise capital, but the terms can be complex and may not always be favorable to existing shareholders.

Comparison to Industry Standards

• Similar agreements are often seen with small-cap companies that need to raise capital quickly.
• The discount to market price is a common feature in these types of agreements, but the specific percentages and floor price can vary.
• The use of VWAP is a standard method for calculating the purchase price in these agreements.
• The floor price of $0.25 is a common feature to protect the company from extreme price drops.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares at a discounted price.
• The company may benefit from the capital raised through the sale of shares.

Next Steps

• United Health Products may issue share price purchase notices to White Lion Capital.
• White Lion Capital may purchase shares under the terms of the amended agreement.

Key Dates

Keywords

Common Stock Purchase Agreement, White Lion Capital, Stock Purchase, Share Price, VWAP, Dilution, Capital Raise